Clinical evidence from the PEMBRO-RT trial further supports this synergy, where SBRT combined with pembrolizumab doubled the ORR in PD-L1-negative NSCLC compared to ICIs alone (9). This evidence concerns the gene CD274 and non-small cell lung carcinoma.